Stockhead’s health and biotech expert Tim Boreham is back in the studio for another instalment of the Health Kick Podcast.

GRI Bio bolsters IP portfolio with granting of two global patents for Europe & Japan: La Jolla, California Wednesday, April 2, 2025, 14:00 Hrs [IST] GRI Bio, Inc., a biotechnology ...

The Independent Data Monitoring Committee (IDMC) has recommended to continue study as planned as there are no safety concerns seen in the data ...

Activation of dNKT leads to a dendritic cell-mediated inhibition of type 1 invariant NKT (iNKT) cells. Japan application No. 2023-000750 titled, “Prevention and Treatment of Inflammatory Conditions.” ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

1 Department of Dermatology, The First Hospital of Shanxi Medical University, Taiyuan, Shanxi, China 2 Department of Dermatology, Qingdao Municipal Hospital, Qingdao, Shandong, China Objective: This ...

PGRE opened at $4.16 on Tuesday. The company has a debt-to-equity ratio of 0.91, a current ratio of 4.45 and a quick ratio of 4.45. The firm has a fifty day moving average price of $4.54 and a 200 ...

MiNK Therapeutics, Inc. (NASDAQ:INKT) Q4 2024 Earnings Call Transcript March 18, 2025 MiNK Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.62 EPS, expectations were $-0.5 ...

MiNK Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of allogeneic invariant natural killer T cell therapies to ...